In the light of these two failed clinical trials with α4β2 nAChR agonists, another clarification could, however, be that the α4β2 nAChR subtype may only play a minor role on cognitive processes in AD, and α7 nAChR is therefore a more suitable target (Kim et al., 2014). The gene discussed is CHRNA7; the disease is Alzheimer disease.